Game On Mole is back this summer!
13 November 2020
The edgy Game On Mole campaign leverages the iconic Aussie catch-cry ‘game on, mole’, encouraging young Australians to check their skin for changes and then seek medical advice if they notice any changes.
It calls on Aussies to don a limited-edition ‘Game On Mole’ T-shirt and share selfies on social media tagged #gameonmole to generate life-saving conversations around sun safety and skin health.
With one Australian expected to be diagnosed with melanoma every half an hour this year, Olympian and melanoma survivor, Cate Campbell, is once again fronting the campaign.
‘I am living proof that early detection is vital to saving lives from melanoma. We need to be having discussions about sun-safety and checking your skin for changes, and I encourage all Aussies to buy a t-shirt, wear it proudly, and start those life-saving conversations.’
CEO of Melanoma Institute Australia, Matthew Browne, said the campaign uses Australian humour to relay a serious message.
‘We know Australians love a laugh almost as much as they love soaking up the sun. But melanoma is no laughing matter, with one Australian dying from the disease every five hours and it being the most common cancer impacting 15 to 39 year olds.
‘The strength of this campaign lies in its capacity to empower all Australians to be a part of the solution by wearing a t-shirt that begs the question ‘what is that about?’ It’s a great conversation starter about what is largely a preventable disease.’
This year’s campaign includes a range of new t-shirt designs giving people a variety of ways to spread the ‘Game On Mole’ message. T-shirt sales also help fund ongoing research by Melanoma Institute Australia into new treatments to save lives from melanoma.
For more information, please contact:
Jennifer Durante |Melanoma Institute Australia | 0412 798 990 | firstname.lastname@example.org
The best ever results seen in metastatic melanoma treatment have been presented at the International ASCO Conference.
We sat down for a short Q&A with our Clinical Research Fellow Sangeetha Ramanujam.
Today marks International Clinical Trials Day held on May 20 each year celebrating how far clinicians have come in the field of research.
We sat down with MIA Practice Manager, Sherrie D'Souza and got an insight into the day of life of her role.
Dr Long was nomitated for the InStyle Women In Style Awards in the Science and Environment category.
The Federal Government’s 2015-16 Budget was announced this week with a boost for medical research funding.
The Association's members include prominent surgeons from around the world.
MIA leads the world-first study that finds anti–PD-1 antibody pembrolizumab increases the survival of patients
This is a landmark study, the first in a class of drugs that will change the future of treatment for all cancers.
Australia is the first country in the world to register anti-PD1 for the first line treatment of unresectable or metastatic melanoma in adults.
We have a winner!
Professor John Thompson, Executive Director at Melanoma Institute Australia, was one of 116 fellows appointed to the new Australian Academy of Health and Medical Sciences at a ceremony in Canberra on the 25th March.
Federal Minister for Health, the Hon. Sussan Ley, announced more than $14 million in funding for a research program to study the molecular determinants of risk, progression and treatment response in melanoma.
If you would like to download a bib for your Melanoma March, we have a selection for you to choose from, print and bring along with you on the day.
Manly Melanoma March has changed to a new location.
We did a short Q&A with two sisters who are raising funds for Melanoma March after sadly losing their mother in 2009. This is their second march and they have shared with us their fundraising tips.
We want to share with you what your valuable Melanoma March donation and fundraising goes towards and our Research Director, Graham Mann explains the national research project the funds will be going towards.
Evaluation of Groin Lymphadenectomy Extent for Metastatic Melanoma (EAGLE FM) clinical trial has recruited its first patient.
You are invited to provide comments for consideration by the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC will consider the registration of the anti-PD1 drug, Keytruda (pembrolizumab) at the next meeting in March.
Melanoma patient Joel Allsop was congratulated today on completing his participation in the international surgical clinical trial, known as MSLT-II. He was the first person in the world to complete the 10 years of follow-up for this trial.